Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claim evaluation largely aligns with the FDA label sections 4.x and 5.x, correctly identifying contraindications, boxed warnings, and major drug interactions. Non-contradictory nuances are largely accurate. Notable gaps include explicit coverage of all NO donors (nitrites) under 4.1, absence of numeric BP thresholds beyond general “uncontrolled hypertension,” and explicit pregnancy/pediatric safety language.
Category Scores
Accurate Statements
Cialis is contraindicated with nitrates (4.1).
4.1
Hypersensitivity to tadalafil is contraindicated (4.2).
4.2
Riociguat (GC stimulator) concomitant use is contraindicated with PDE5 inhibitors (4.3).
4.3
MI within the last 90 days is not recommended (5.1).
5.1
Unstable angina is not recommended (5.1).
5.1
Uncontrolled hypotension (<90/50 mmHg) is not recommended (5.1).
5.1
Uncontrolled hypertension lacks a numeric threshold in the label (contextual warning exists) (5.1).
5.1
New York Heart Association Class 2 or greater heart failure is not recommended (5.1).
5.1
Cardiovascular risk with sexual activity is acknowledged; caution advised (5.1).
5.1
Hereditary degenerative retinal disorders (retinitis pigmentosa) are not recommended; retinal risk messaging is present (5.4).
5.4
Hepatic impairment considerations exist; severe hepatic impairment guidance is implied (5.8).
5.8
Renal impairment considerations, including ESRD considerations, are addressed (5.7).
5.7
Concomitant riociguat use is prohibited due to amplified hypotensive effects (4.3).
4.3
Unsupported Statements
Nitric oxide donors are treated identically to nitrates in the label.
Label explicitly references nitrates; does not explicitly enumerate all NO donors (nitrites) within 4.1.
cGMP mechanism of action for tadalafil is described in the label.
Label does not provide mechanistic MOA in the cited sections.
All nitrites (e.g., amyl nitrite) are explicitly covered as contraindicated with Cialis.
Provided text covers nitrates; amyl nitrite/nitrites are not explicitly addressed in the excerpts.
Explicit dosing adjustments for end-stage renal disease are described in 5.7/5.8.
Label excerpt mentions renal/hepatic impairment but does not provide dialysis-specific dosing in the provided sections.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Explicit pregnancy safety language and pediatric safety considerations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Overall alignment is strong with label; minor omissions are non-contradictory and relate to labeling granularity rather than safety misstatements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Explicitly enumerate all NO-donor categories (nitrates, nitrites, and NO-donor medications) or add a general NO-donor contraindication; clarify numeric BP thresholds for hypertension in 5.1; add explicit pregnancy and pediatric safety language; confirm explicit dialysis-specific guidance if applicable.